Functional Gut Clinic's new branch to digest all odds in the research space

Introduction

Functional Gut Clinic (FGC), the expert face of modern gastrointestinal diagnostics, which also provides effective tests for conditions like leaky gut, reflux and IBS with the help of technology such as manometry, breath test, etc., is highly promoting its personalised clinical care. The company has a strong footprint in the UK for its effective and valuable solutions for various crucial gut issues.

The company is a part of the research into modern digestive health treatments and diagnostics. The impeccable therapists, gastroenterologists and physiologists are the main strength of the company.

Announcement

The Functional Gut Clinic (FGC) introduced its new GI Clinical Trials division that will be the first ever to bring all clinical research providers under one roof, responsible for the better digestive health of individuals. This new branch will give broad space and time to the clinical researchers to perform their best in this encouraging and undisruptive setting.

FGC’s entry into the clinical market

FGC promise main advantages that will be unique by that of the common CROs. This division will be a huge volunteer investment for the effective digestive-health research, involving 5,000 selected individuals struggling from this digestive health issues. The recruitment process will gather potential brains who will meet full enrolment in six months after proving their role in recent studies.

FGC’s commendable diagnostic expertise serves over 12,000 physiology tests every year, following UKAS-accredited GI physiology service marks excellence in the UK to do so. With this level of expertise, the participants will be attended to quickly with accuracy that will boost the study start-up.

This convincing potential volume helps the company to speed up its hiring process, serve best in class digestive-health trials and screen precisely throughout various UK sites. These advantages are a boon a confident built up to the company’s new start in the clinical line.

This idea emerges just after the successful Phase 2a IBS study for EnteroBiotix. This study was a turning point and a push for the company to expand its specialisation and approaches to the greater and fundamental part of the healthcare sector, the ‘Clinical space’.

Founder of the Functional Gut Clinic, Professor Anthony Hobson, said, “The digestive health research is somewhat slowed due to the challenges in understanding the patient's physiology deeply and also searching for the right patient has become a complex task.”